IKNL werkte in 2015 mee aan in totaal 177 wetenschappelijke publicaties

Overzicht wetenschappelijke publicaties in 2015 per tumorsoort:

Kanker, algemeen	30
Bloed, beenmerg & lymfeklieren	17
Borstkanker	36
Bot & weke delen	1
Centraal zenuwstelsel	1
Endocriene klieren	1
Hoofd & hals	4
Huidkanker	2
Onderste luchtwegen	7
Spijsverteringsorganen	49
Urinewegen	10
Vrouwelijke geslachtsorganen	19

Meer informatie over deze publicaties is verkrijgbaar via bibliotheek@iknl.nl

Onderwerpen publicaties

• genetische variaties en het risico op ontstaan van kanker
• preventie van (terugkeer van) kanker
• het vóórkomen van en overleving na kanker
• diagnostiek en behandeling in alle stadia van de ziekte
• neveneffecten, variërend van tijdens en kort na behandeling, tot aan decennia na behandeling
• patronen van uitzaaiing en terugkeer van kanker
• trends over de tijd en variatie tussen patiëntengroepen, instellingen, regio’s en landen 
• adherentie aan richtlijnen en indicatoren, maar ook effect daarvan op klinische praktijk en uitkomsten van de ziekte
• effectiviteit en mate van samenwerking en concentratie in de oncologische zorg
• kosteneffectiviteit van behandeling
• (toekomst)scenario’s voor zorgconsumptie
• de invloed van kanker en behandeling en neveneffecten op kwaliteit van leven en overleving
• lifestyle factoren en medicatiegebruik en de relatie met ontstaan en beloop van kanker
• klinische trials
• methodologie van onderzoek naar kanker en kankerregistraties in het algemeen
• informatievoorziening aan patiënten
• kwaliteit van de palliatieve zorg

Bijdrage aan verbetering kankerzorg

Deze publicaties dragen direct bij aan verbetering van de kankerzorg in Nederland en daarbuiten en daarmee aan de overleving en kwaliteit van leven van patiënten met kanker door: 

• het identificeren van gebieden waar verbetering van de oncologische zorg mogelijk en/of noodzakelijk is
• het kritisch evalueren van de effectiviteit van preventie, diagnostiek, behandelingen en andere interventies
• het evalueren en aanpassen van behandelrichtlijnen 
• het stimuleren van (regionale) samenwerking
• het geven van spiegelinformatie aan zorgverleners.

Nederlandse Kankerregistratie als gegevensbron

Een groot deel van de publicaties heeft de Nederlandse Kankerregistratie (NKR cijfers) als gegevensbron. Vaak wordt via koppeling van gegevens uit andere databronnen relevante informatie op een effectieve manier toegevoegd aan de NKR en vice versa. Onafhankelijke en getrainde datamanagers van IKNL leggen de data uit medische dossiers in de NKR vast, zonder aanvullende registratielast voor het medisch personeel. De data uit de NKR zijn beschikbaar voor zorg- en onderzoeksinstellingen.

Vanaf 2016 wordt het gehele ziektebeloop van patiënten met kanker nog beter in kaart gebracht. Gegevens die nu (inter)nationaal nauwelijks voorhanden zijn op populatieniveau, zoals hoe vaak, waar en wanneer de ziekte terugkomt en gedetailleerde informatie over systemische therapie, worden steeds vaker standaard onderdeel van de NKR. 

Bronnen en onderwerpen

De publicaties kunnen gebaseerd zijn op data van patiënten uit een of enkele ziekenhuizen, tot en met regionale en landelijke studies. Ook maken de NKR-data en IKNL-medewerkers deel uit van Europese of wereldwijde initiatieven, waardoor de Nederlandse oncologische zorg in internationaal perspectief kan worden geplaatst.

De gepubliceerde studies omvatten alle voorkomende kankersoorten, ook zeldzame. In 2015 richtten 49 publicaties zich met name op maligniteiten van de spijsverteringsorganen, 36 hadden betrekking op borstkanker en 19 op de vrouwelijke geslachtsorganen. 30 publicaties handelden over meerdere kankervormen of kanker in het algemeen. Daarnaast zijn er jaarlijks tientallen publicaties waarbij NKR-data worden gebruikt maar waarbij geen IKNL-medewerkers betrokken zijn als (co-)auteur. Deze zijn in het totaal van 177 artikelen niet meegeteld.

Impact van de publicaties

Het merendeel van de publicaties verscheen in 2015 in internationale medische tijdschriften met een hoge impactfactor (top 25% van het desbetreffende vakgebied). De impactfactor van een tijdschrift geeft aan hoe vaak wordt verwezen naar studies gepubliceerd in dat tijdschrift: dat is een maat voor de mate waarin publicaties impact hebben in de zorg en/of de onderzoekswereld. De gemiddelde impactfactor (IF) van alle IKNL-publicaties in 2015 bedroeg afgerond 6. 

Medewerkers van IKNL publiceerden in 2015 in toptijdschriften zoals The New England Journal of Medicine (n=1, IF 55), The Lancet (n=3, IF 45), Nature Genetics (n=3, IF 29), The Lancet Oncology (n=1, IF 25), Journal of Clinical Oncology (n=4, IF 18), European urology (n=1, IF 14), Journal of the National Cancer Institute (n=3, IF=13), en Leukemia (n=3, IF=10). 

Daarnaast verschenen in 2015 19 publicaties in een van de hoogst aangeschreven Europese algemeen oncologische tijdschriften, het European Journal of Cancer (impact factor (IF) 5.4). In het als vijfde van alle tweehonderd chirurgisch georiënteerde tijdschriften gerangschikte British Journal of Surgery (IF 5.5) verschenen zeven artikelen, in het wereldwijd nummer een chirurgisch-oncologisch tijdschrift Annals of Surgical Oncology (IF 4) vier  artikelen. 

Overzicht publicaties

Kanker, algemeen

• Aaldriks AA, Maartense E, Nortier HJ, van der Geest LG, le Cessie S, Tanis BC, Portielje JE, Ypma P, Giltay EJ. Prognostic factors for the feasibility of chemotherapy and the Geriatric Prognostic Index (GPI) as risk profile for mortality before chemotherapy in the elderly. Acta Oncol. 2015 Aug 25:1-9.

• Baili P, Di Salvo F, Marcos-Gragera R, Siesling S, Mallone S, Santaquilani M, Micheli A, Lillini R, Francisci S; EUROCARE-5 Working Group. Age and case mix-standardised survival for all cancer patients in Europe 1999-2007: Results of EUROCARE-5, a population-based study. Eur J Cancer. 2015 Sep 6. pii: S0959-8049(15)00705-4.

• Beekers N, Husson O, Mols F, van Eenbergen M, van de Poll-Franse LV. Symptoms of Anxiety and Depression Are Associated With Satisfaction With Information Provision and Internet Use Among 3080 Cancer Survivors: Results of the PROFILES Registry. Cancer Nurs. 2015 Sep-Oct;38(5):335-42.

• Beijers AJ, Mols F, van den Hurk CJ, Vreugdenhil A. Are chemotherapy-associated symptoms underestimated? A view beyond common toxicity criteria. Acta Oncol. 2015 Sep 11:1-3.

• Borras JM, Barton M, Grau C, Corral J, Verhoeven R, Lemmens V, van Eycken L, Henau K, Primic-Zakelj M, Strojan P, Trojanowski M, Dyzmann-Sroka A, Kubiak A, Gasparotto C, Defourny N, Malicki J, Dunscombe P, Coffey M, Lievens Y. The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project. Radiother Oncol. 2015 Jul;116(1):45-50.

• Borras JM, Lievens Y, Dunscombe P, Coffey M, Malicki J, Corral J, Gasparotto C, Defourny N, Barton M, Verhoeven R, van Eycken L, Primic-Zakelj M, Trojanowski M, Strojan P, Grau C. The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis. Radiother Oncol. 2015 Jul;116(1):38-44.

• Coebergh JW, van den Hurk C, Rosso S, Comber H, Storm H, Zanetti R, Sacchetto L, Janssen-Heijnen M, Thong M, Siesling S, van den Eijnden-van Raaij J. EUROCOURSE lessons learned from and for population-based cancer registries in Europe and their programme owners: Improving performance by research programming for public health and clinical evaluation. Eur J Cancer. 2015 Jun;51(9):997-1017.

• Coebergh JW, van den Hurk C, Louwman M, Comber H, Rosso S, Zanetti R, Sacchetto L, Storm H, van Veen EB, Siesling S, van den Eijnden-van Raaij J. EUROCOURSE recipe for cancer surveillance by visible population-based cancer RegisTrees® in Europe: From roots to fruits. Eur J Cancer. 2015 Jun;51(9):1050-63.

• Daanen HA, Peerbooms M, van den Hurk CJ, van Os B, Levels K, Teunissen LP, Breed WP. Core temperature affects scalp skin temperature during scalp cooling. Int J Dermatol. 2015 Aug;54(8):916-21.

• Dirven L, van de Poll-Franse LV, Aaronson NK, Reijneveld JC. Controversies in defining cancer survivorship. Lancet Oncol. 2015 Jun;16(6):610-2.

• Hoek P, Grandjean I, Verhagen CA, Jansen-Landheer ML, Schers HJ, Galesloot C, Vissers KC, Engels Y, Hasselaar JG. Addressing Palliative Sedation during Expert Consultation: A Descriptive Analysis of the Practice of Dutch Palliative Care Consultation Teams. PLoS One. 2015 Aug 24;10(8):e0136309.

• Husson O, Mols F, van de Poll-Franse L, de Vries J, Schep G, Thong MS. Variation in fatigue among 6011 (long-term) cancer survivors and a normative population: a study from the population-based PROFILES registry. Support Care Cancer. 2015 Jul;23(7):2165-74.

• Kilsdonk M, Siesling S, Otter R, Harten Wv. Evaluating the impact of accreditation and external peer review. Int J Health Care Qual Assur. 2015 Oct 12;28(8):757-77.

• Kilsdonk MJ, Siesling S, Otter R, van Harten WH. Two decades of external peer review of cancer care in general hospitals; the Dutch experience. Cancer Med. 2015 Dec 29.

• Kok SJ, van Laarhoven, HW, Lemmens, VE, Schroten, C. International variation in diagnostic and treatment guidelines for carcinoma unknown primary. Int j Cancer Res. 2015 Sept.

• Nicolaije KA, Ezendam NP, Vos MC, Pijnenborg JM, Boll D, Boss EA, Hermans RH, Engelhart KC, Haartsen JE, Pijlman BM, van Loon-Baelemans IE, Mertens HJ, Nolting WE, van Beek JJ, Roukema JA, Zijlstra WP, Kruitwagen RF, van de Poll-Franse LV. Impact of an Automatically Generated Cancer Survivorship Care Plan on Patient-Reported Outcomes in Routine Clinical Practice: Longitudinal Outcomes of a Pragmatic, Cluster Randomized Trial. J Clin Oncol. 2015 Nov 1;33(31):3550-9.

• Oosten AW, Oldenmenger WH, Mathijssen RH, van der Rijt CC. A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome Measures.J Pain. 2015 Oct;16(10):935-46. Review.

• Rajan A, Wind A, Saghatchian M, Thonon F, Boomsma F, van Harten WH. Staff perceptions of change resulting from participation in a European cancer accreditation programme: a snapshot from eight cancer centres. Ecancermedicalscience. 2015 Jun 23;9:547.

• Sant M, Minicozzi P, Primic-Žakelj M, Otter R, Francisci S, Gatta G, Berrino F, De Angelis R. Cancer survival in Europe, 2000-2007: Doing better, feeling worse? Eur J Cancer. 2015 Sep 4. pii: S0959-8049(15)00809-6.

• Steins Bisschop CN, Courneya KS, Velthuis MJ, Monninkhof EM, Jones LW, Friedenreich C, van der Wall E, Peeters PH, May AM. Control group design, contamination and drop-out in exercise oncology trials: a systematic review. PLoS One. 2015 Mar 27;10(3):e0120996.

• van de Wal M, van de Poll-Franse L, Prins J, Gielissen M. Does fear of cancer recurrence differ between cancer types? A study from the population-based PROFILES registry. Psychooncology. 2015 Oct 14.

• van den Hurk CJ, Winstanley J, Young A, Boyle F. Measurement of chemotherapy-induced alopecia-time to change. Support Care Cancer. 2015 May;23(5):1197-9.

• van den Hurk C, de Beer F, Dries W, van de Sande I, Hermsen N, Breed W, van der Sangen M. No prevention of radiotherapy-induced alopecia by scalp cooling. Radiother Oncol. 2015 Oct;117(1):193-4.

• van den Hurk C, Breed W, Dercksen W. Nonpegylated liposomal doxorubicin: reduction in cardiotoxicity, although still severe alopecia. Anticancer Drugs. 2015 Jul;26(6):687.

• van der Zwan JM, van Dijk BA, Visser O, van Krieken HJ, Capocaccia R, Siesling S. Rare cancers in The Netherlands: a population-based study. Eur J Cancer Prev. 2015 May 8.

• van Veen MR, Beijer S, Adriaans AM, Vogel-Boezeman J, Kampman E. Development of a Website Providing Evidence-Based Information About Nutrition and Cancer: Fighting Fiction and Supporting Facts Online. JMIR Res Protoc. 2015 Sep 8;4(3):e110.

• Vissers PA, Falzon L, van de Poll-Franse LV, Pouwer F, Thong MS. The impact of having both cancer and diabetes on patient-reported outcomes: a systematic review and directions for future research. J Cancer Surviv. 2015 Oct 1.

• Wijnhoven MN, Terpstra WE, van Rossem R, Haazer C, Gunnink-Boonstra N, Sonke GS, Buiting HM. Bereaved relatives' experiences during the incurable phase of cancer: a qualitative interview study. BMJ Open. 2015 Nov 25;5(11):e009009.

• Zanders MM, Haak HR, van Herk-Sukel MP, van de Poll-Franse LV, Johnson JA. Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia. 2015 May;58(5):951-60.

• Zanders MM, Haak HR, van Herk-Sukel MP, van de Poll-Franse LV, Johnson JA. Impact of cancer on use of glucose-lowering drug treatment in individuals with diabetes: potential mechanisms. Reply to Pouwer F [letter]. Diabetologia. 2015 Jun;58(6):1380-1.

Bloed, beenmerg & lymfeklieren

• Aaldriks AA, Giltay EJ, Nortier JW, van der Geest LG, Tanis BC, Ypma P, le Cessie S, Maartense E. Prognostic significance of geriatric assessment in combination with laboratory parameters in elderly patients with aggressive non-Hodgkin lymphoma.Leuk Lymphoma. 2015 Apr;56(4):927-35.

• Beijers AJ, Vreugdenhil G, Oerlemans S, Eurelings M, Minnema MC, Eeltink CM, van de Poll-Franse LV, Mols F. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. Support Care Cancer. 2015 Dec 3.

• Blommestein HM, Verelst SG, de Groot S, Huijgens PC, Sonneveld P, Uyl-de Groot CA. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. Eur J Haematol. 2016 Feb;96(2):198-208.

• Coebergh JW, Aarts MJ. Klinische epidemiologie van bloed- en lymfeklierkanker in Nederland. In: Leerboek Hematologie (hoofdstuk 22). Lochem : De tijdstroom, 2015. 2^e geh. herz. dr.

• De Angelis R, Minicozzi P, Sant M, Dal Maso L, Brewster DH, Osca-Gelis G, Visser O, Maynadié M, Marcos-Gragera R, Troussard X, Agius D, Roazzi P, Meneghini E, Monnereau A; EUROCARE-5 Working Group. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000-2007: Results of EUROCARE-5 population-based study. Eur J Cancer. 2015 Sep 6. pii: S0959-8049(15)00778-9.

• de Waal EG, de Munck L, Hoogendoorn M, Woolthuis G, van der Velden A, Tromp Y, Vellenga E, Hovenga S. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. Br J Haematol. 2015 Sep 11.

• Dinmohamed AG, van Norden Y, Visser O, Posthuma EF, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry. Leukemia. 2015 Sep 15.

• Dinmohamed AG, Szabó A, van der Mark M, Visser O, Sonneveld P, Cornelissen JJ, Jongen-Lavrencic M, Rijneveld AW. Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival. Leukemia. 2016 Feb;30(2):310-7.

• Dinmohamed AG, Visser O, van Norden Y, Blijlevens NM, Cornelissen JJ, Huls GA, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Ossenkoppele GJ, Löwenberg B, Jongen-Lavrencic M. Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012. Leukemia. 2016 Jan;30(1):24-31.

• Dinmohamed AG, Brink M, Visser O, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M, de Greef GE. Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population-based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012. Br J Haematol. 2015 Nov;171(3):436-9.

• Husson O, Oerlemans S, Mols F, Schep G, van De Poll-Franse LV. High levels of physical activity are associated with lower levels of fatigue among lymphoma patients: Results from the longitudinal PROFILES registry. Acta Oncol. 2015 Mar 9:1-7.

• Oerlemans S, Nijziel MR, van de Poll-Franse LV. Age-related differences in quality of life among patients with diffuse large B-cell lymphoma. Cancer. 2015 Apr 29.

• Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N Engl J Med. 2015 Dec 24;373(26):2499-511.

• Stienen JJ, Hermens RP, Wennekes L, van de Schans SA, van der Maazen RW, Dekker HM, Liefers J, van Krieken JH, Blijlevens NM, Ottevanger PB; PEARL study group. Variation in guideline adherence in non-Hodgkin's lymphoma care: impact of patient and hospital characteristics. BMC Cancer. 2015 Aug 8;15:578.

• Taal W, van der Togt-van Leeuwen AC. Nieuwe richtlijn wervelmetastasen: bij solide tumoren en bij wervellokalisaties van hematologische tumoren. Ned Tijdschr Geneeskd. 2015;159(0):A9101

• Thielen N, Visser O, Ossenkoppele G, Janssen J. Chronic Myeloid Leukaemia in The Netherlands: a Population-Based Study on Incidence, Treatment and Survival in 3,585 Patients from 1989-2012. Eur J Haematol. 2015 Oct 31.

• van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, Kooijman K, Roesink J, van der Maazen R, Darby SC, Aleman BM, van Leeuwen FE. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. J Clin Oncol. 2016 Jan 20;34(3):235-43.

Borstkanker

• Beek MA, te Slaa A, van der Laan L, Mulder PG, Rutten HJ, Voogd AC, Luiten EJ, Gobardhan PD. Reliability of the Inverse Water Volumetry Method to Measure the Volume of the Upper Limb. Lymphat Res Biol. 2015 Jun;13(2):126-30.

• Beek MA, Verheuvel NC, Luiten EJ, Klompenhouwer EG, Rutten HJ, Roumen RM, Gobardhan PD, Voogd AC. Two decades of axillary management in breast cancer. Br J Surg. 2015 Dec;102(13):1658-64.

• de Glas NA, Engels CC, Bastiaannet E, van de Water W, Siesling S, de Craen AJ, van de Velde CJ, Liefers GJ, Merkus JW. Contralateral breast cancer risk in relation to tumor morphology and age-in which patients is preoperative MRI justified? Breast Cancer Res Treat. 2015 Feb;150(1):191-8.

• de Glas NA, Bastiaannet E, de Craen AJ, van de Velde CJ, Siesling S, Liefers GJ, Portielje JE. Survival of older patients with metastasised breast cancer lags behind despite evolving treatment strategies - A population-based study. Eur J Cancer. 2015 Feb;51(3):310-6.

• Ho VK, Gijtenbeek JM, Brandsma D, Beerepoot LV, Sonke GS, van der Heiden-van der Loo M. Survival of breast cancer patients with synchronous or metachronous central nervous system metastases. Eur J Cancer. 2015 Nov;51(17):2508-16.

• Katik S, Gort M, Jobsen JJ, Maduro JH, Struikmans H, Siesling S. Factors influencing time between surgery and radiotherapy: A population based study of breast cancer patients. Breast. 2015 Aug;24(4):468-75.

• Klompenhouwer EG, Weber RJ, Voogd AC, den Heeten GJ, Strobbe LJ, Broeders MJ, Tjan-Heijnen VC, Duijm LE. Arbitration of discrepant BI-RADS 0 recalls by a third reader at screening mammography lowers recall rate but not the cancer detection rate and sensitivity at blinded and non-blinded double reading. Breast. 2015 Oct;24(5):601-7.

• Klompenhouwer EG, Voogd AC, den Heeten GJ, Strobbe LJ, de Haan AF, Wauters CA, Broeders MJ, Duijm LE. Blinded double reading yields a higher programme sensitivity than non-blinded double reading at digital screening mammography: a prospected population based study in the south of The Netherlands. Eur J Cancer. 2015 Feb;51(3):391-9.

• Klompenhouwer EG, Voogd AC, den Heeten GJ, Strobbe LJ, Tjan-Heijnen VC, Broeders MJ, Duijm LE. Discrepant screening mammography assessments at blinded and non-blinded double reading: impact of arbitration by a third reader on screening outcome. Eur Radiol. 2015 Oct;25(10):2821-9.

• Kuijer A, van Bommel AC, Drukker CA, van der Heiden-van der Loo M, Smorenburg CH, Westenend PJ, Linn SC, Rutgers EJ, Elias SG, van Dalen T. Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study. Genet Med. 2015 Nov 19.

• Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol. 2016 Feb;27(2):256-62.

• Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015 Apr 28;112(9):1445-1451.

• Luiten JD, Beek MA, Voogd AC, Gobardhan PD, Luiten EJ. Iodine seed- versus wire-guided localization in breast-conserving surgery for non-palpable ductal carcinoma in situ. Br J Surg. 2015 Dec;102(13):1665-9.

• Mauguen A, Rachet B, Mathoulin-Pélissier S, Lawrence GM, Siesling S, MacGrogan G, Laurent A, Rondeau V. Validation of death prediction after breast cancer relapses using joint models. BMC Med Res Methodol. 2015 Apr 1;15(1):27.

• Moossdorff M, Vugts G, Maaskant-Braat AJ, Strobbe LJ, Voogd AC, Smidt ML, Nieuwenhuijzen GA. Contralateral lymph node recurrence in breast cancer: Regional event rather than distant metastatic disease. A systematic review of the literature. Eur J Surg Oncol. 2015 Sep;41(9):1128-36.

• Peerbooms M, van den Hurk CJ, Breed WP. Familiarity, opinions, experiences and knowledge about scalp cooling: a Dutch survey among breast cancer patients and oncological professionals. Asia Pac J Oncol Nurs 2015;2:35-41

• Pleijhuis RG, Kwast AB, Jansen L, de Vries J, Wiggers T, Siesling S, van Dam GM. Validity of the BreastConservation! nomogram evaluated. Breast. 2015 Oct;24(5):540-2.

• Ruiz A, Wicherts D, Adam R, Siesling S, Linn S, Hillegersberg R. Resectie van levermetastasen bij borstkanker. Ned Tijdschr Geneeskd. 2015;159:A8453.

• Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM. Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients. BMJ. 2015 Oct 6;351:h4901.

• Travier N, Velthuis MJ, Steins Bisschop CN, van den Buijs B, Monninkhof EM, Backx F, Los M, Erdkamp F, Bloemendal HJ, Rodenhuis C, de Roos MA, Verhaar M, Ten Bokkel Huinink D, van der Wall E, Peeters PH, May AM. Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial. BMC Med. 2015 Jun 8;13:121.

• Truin W, Vugts G, Roumen RM, Maaskant-Braat AJ, Nieuwenhuijzen GA, van der Heiden-van der Loo M, Tjan-Heijnen VC, Voogd AC. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer. Ann Surg Oncol. 2016 Jan;23(1):51-7.

• van den Broek AJ, van 't Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, Smit VT, Cornelisse CJ, van Beek M, Janssen-Heijnen ML, Seynaeve C, Westenend PJ, Jobsen JJ, Siesling S, Tollenaar RA, van Leeuwen FE, Schmidt MK. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. J Clin Oncol. 2016 Feb 10;34(5):409-18.

• van den Hoven I, van Klaveren D, Voogd AC, Vergouwe Y, Tjan-Heijnen V, Roumen RM. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients. Clin Breast Cancer. 2015 Sep 21. pii: S1526-8209(15)00214-1.

• van den Hoven I, Kuijt G, Roumen R, Voogd A, Steyerberg EW, Vergouwe Y. A head to head comparison of nine tools predicting non-sentinel lymph node status in sentinel node positive breast cancer women. J Surg Oncol. 2015 Aug;112(2):133-8.

• van den Hoven I, Voogd AC, Roumen RM. A Paradigm Shift in Axillary Breast Cancer Treatment; From "Treat All-Except," Toward "Treat None-Unless". Clin Breast Cancer. 2015 Dec;15(6):399-402.

• van der Heiden-van der Loo M, de Munck L, Sonke GS, van Dalen T, van Diest PJ, van den Bongard HJ, Peeters PH, Rutgers EJ. Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients: Identification rate and influence on axillary treatment. Eur J Cancer. 2015 May;51(8):915-21.

• van der Heiden-van der Loo M, Siesling S, Wouters MW, van Dalen T, Rutgers EJ, Peeters PH. The Value of Ipsilateral Breast Tumor Recurrence as a Quality Indicator: Hospital Variation in the Netherlands. Ann Surg Oncol. 2015 Dec;22 Suppl 3:522-8.

• van Vulpen JK, Peeters PH, Velthuis MJ, van der Wall E, May AM. Effects of physical exercise during adjuvant breast cancer treatment on physical and psychosocial dimensions of cancer-related fatigue: A meta-analysis. Maturitas. 2016 Mar;85:104-11. Review.

• van Waart H, Stuiver MM, van Harten WH, Geleijn E, Kieffer JM, Buffart LM, de Maaker-Berkhof M, Boven E, Schrama J, Geenen MM, Meerum Terwogt JM, van Bochove A, Lustig V, van den Heiligenberg SM, Smorenburg CH, Hellendoorn-van Vreeswijk JA, Sonke GS, Aaronson NK. Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial. J Clin Oncol. 2015 Jun 10;33(17):1918-27.

• Vissers PA, Cardwell CR, van de Poll-Franse LV, Young IS, Pouwer F, Murray LJ. The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes. Breast Cancer Res Treat. 2015 Apr;150(2):427-37.

• Vos EL, Voogd AC, Verhoef C, Siesling S, Obdeijn IM, Koppert LB. Benefits of preoperative MRI in breast cancer surgery studied in a large population-based cancer registry. Br J Surg. 2015 Dec;102(13):1649-57.

• Vugts G, Maaskant-Braat AJ, Voogd AC, van Riet YE, Roumen RM, Luiten EJ, Rutgers EJ, Wyndaele D, Rutten HJ, Nieuwenhuijzen GA. Improving the Success Rate of Repeat Sentinel Node Biopsy in Recurrent Breast Cancer. Ann Surg Oncol. 2015 Aug 11.

• Vugts G, Maaskant-Braat AJ, Voogd AC, van Riet YE, Luiten EJ, Rutgers EJ, Rutten HJ, Roumen RM, Nieuwenhuijzen GA. Repeat sentinel node biopsy should be considered in patients with locally recurrent breast cancer. Breast Cancer Res Treat. 2015 Oct;153(3):549-56.

• Weber RJ, Klompenhouwer EG, Voogd AC, Strobbe LJ, Broeders MJ, Duijm LE. Comparison of the diagnostic workup of women referred at non-blinded or blinded double reading in a population-based screening mammography programme in the south of the Netherlands. Br J Cancer. 2015 Sep 29;113(7):1094-8.

• Witteveen A, Vliegen IM, Sonke GS, Klaase JM, IJzerman MJ, Siesling S. Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients.Breast Cancer Res Treat. 2015 Aug;152(3):627-36.

• Witteveen A, Kwast AB, Sonke GS, IJzerman MJ, Siesling S. Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval. PLoS One. 2015 Apr 10;10(4):e0120832.

Bot & weke delen

• Vlenterie M, Ho VK, Kaal SE, Vlenterie R, Haas R, van der Graaf WT Age as an independent prognostic factor for survival of localised synovial sarcoma patients. Br J Cancer. 2015 Dec 1;113(11):1602-6.

Centraal zenuwstelsel

• Visser O, Ardanaz E, Botta L, Sant M, Tavilla A, Minicozzi P; EUROCARE-5 Working Group. Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study. Eur J Cancer. 2015 Sep 5. pii: S0959-8049(15)00712-1.

Endocriene klieren

• Tamminga SJ, Bültmann U, Husson O, Kuijpens JL, Frings-Dresen MH, de Boer AG. Employment and insurance outcomes and factors associated with employment among long-term thyroid cancer survivors: a population-based study from the PROFILES registry. Qual Life Res. 2015 Sep 22.

Hoofd & hals

• Lacko M, Voogd AC, van de Goor RC, Roelofs HM, Te Morsche RH, Bouvy ND, Peters WH, Manni JJ. Genetic polymorphisms in UDP-glucuronosyltransferase 1A6 and 1A7 and the risk for benign Warthin's tumors of the parotid gland. Head Neck. 2015 Apr 20.

• Melchers LJ, Mastik MF, Samaniego Cameron B, van Dijk BA, de Bock GH, van der Laan BF, van der Vegt B, Speel EJ, Roodenburg JL, Witjes MJ, Schuuring E. Detection of HPV-associated oropharyngeal tumours in a 16-year cohort: more than meets the eye. Br J Cancer. 2015 Apr 14;112(8):1349-57.

• Pietersma NS, de Bock GH, de Visscher JG, Roodenburg JL, van Dijk BA. No evidence for a survival difference between upper and lower lip squamous cell carcinoma. Int J Oral Maxillofac Surg. 2015 May;44(5):549-54.

• Timmermans AJ, van Dijk BA, Overbeek LI, van Velthuysen MF, van Tinteren H, Hilgers FJ, van den Brekel MW. Trends in treatment and survival for advanced laryngeal cancer: A 20-year population-based study in The Netherlands. Head Neck. 2015 Aug 28.

Huidkanker

• van der Leest RJ, Zoutendijk J, Nijsten T, Mooi WJ, van der Rhee JI, de Vries E, Hollestein LM. Increasing time trends of thin melanomas in The Netherlands: What are the explanations of recent accelerations? Eur J Cancer. 2015 Dec;51(18):2833-41.

• Winstanley JB, Young TE, Boyle FM, Bergenmar M, Bottomley A, Burmeister B, Campana LG, Garioch JJ, King M, Nikolic DV, van de Poll-Franse LV, Saw R, Thompson JF, White EG; European Organisation for Research and Treatment of Cancer (EORTC). Quality of Life Group. Cross-cultural development of a quality-of-life measure for patients with melanoma: phase 3 testing of an EORTC Melanoma Module. Melanoma Res. 2015 Feb;25(1):47-58.

Onderste luchtwegen

• Chen LS, Aben KK, Bierut LJ et al. CHRNA5 Risk Variant Predicts Delayed Smoking Cessation and Earlier Lung Cancer Diagnosis-A Meta-Analysis. J Natl Cancer Inst. 2015 Apr 14;107(5). pii: djv100. Review.

• Damhuis RA, Khakwani A, De Schutter H, Rich AL, Burgers JA, van Meerbeeck JP. Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England. Lung Cancer. 2015 Aug;89(2):212-7.

• Derks JL, Hendriks LE, Buikhuisen WA, Groen HJ, Thunnissen E, van Suylen RJ, Houben R, Damhuis RA, Speel EJ, Dingemans AC. Clinical features of large cell neuroendocrine carcinoma: a population-based overview. Eur Respir J. 2016 Feb;47(2):615-24.

• Hendriks LE, Derks JL, Postmus PE, Damhuis RA, Houben RM, Troost EG, Hochstenbag MM, Smit EF, Dingemans AC. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study. Eur J Cancer. 2015 Nov;51(17):2534-44.

• Janssen-Heijnen ML, van Erning FN, De Ruysscher DK, Coebergh JW, Groen HJ. Variation in causes of death in patients with non-small cell lung cancer according to stage and time since diagnosis. Ann Oncol. 2015 May;26(5):902-7.

• Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, Keijser A, Faivre-Finn C, Senan S. Radiotherapy for extensive stage small-cell lung cancer - Authors' reply. Lancet. 2015 Apr 4;385(9975):1292-3.

• Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, Keijser A, Faivre-Finn C, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015 Jan 3;385(9962):36-42. Erratum in: Lancet. 2015 Jan 3;385(9962):28.

 Spijsverteringsorganen

• Bakens MJ, van Gestel YR, Bongers M, Besselink MG, Dejong CH, Molenaar IQ, Busch OR, Lemmens VE, de Hingh IH; Dutch Pancreatic Cancer Group. Hospital of diagnosis and likelihood of surgical treatment for pancreatic cancer. Br J Surg. 2015 Oct 5.

• Bernards N, Creemers GJ, Huysentruyt CJ, de Hingh IH, van der Schelling GP, de Bruïne AP, Lemmens VE. The relevance of pathological verification in suspected pancreatic cancer. Cancer Epidemiol. 2015 Apr;39(2):250-5.

• Bos AC, van Erning FN, van Gestel YR, Creemers GJ, Punt CJ, van Oijen MG, Lemmens VE. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur J Cancer. 2015 Nov;51(17):2553-61.

• Bours MJ, Beijer S, Winkels RM, van Duijnhoven FJ, Mols F, Breedveld-Peters JJ, Kampman E, Weijenberg MP, van de Poll-Franse LV. Dietary changes and dietary supplement use, and underlying motives for these habits reported by colorectal cancer survivors of the Patient Reported Outcomes Following Initial Treatment and Long-Term Evaluation of Survivorship (PROFILES) registry. Br J Nutr. 2015 Jul;114(2):286-96.

• Homan J, Bökkerink GM, Aarts MJ, Lemmens VE, van Lijnschoten G, Rutten HJ, Wijsman JH, Nagtegaal ID, de Wilt JH. Variation in circumferential resection margin: Reporting and involvement in the South-Netherlands. Eur J Surg Oncol. 2015 Nov;41(11):1485-92.

• Horevoorts NJ, Vissers PA, Mols F, Thong MS, van de Poll-Franse LV. Response rates for patient-reported outcomes using web-based versus paper questionnaires: comparison of two invitational methods in older colorectal cancer patients. J Med Internet Res. 2015 May 7;17(5):e111.

• Hugen N, van de Velde CJ, Bosch SL, Fütterer JJ, Elferink MA, Marijnen CA, Rutten HJ, de Wilt JH, Nagtegaal ID. Modern Treatment of Rectal Cancer Closes the Gap Between Common Adenocarcinoma and Mucinous Carcinoma.http://www.ncbi.nlm.nih.gov/pubmed/25564178 Ann Surg Oncol. 2015 Aug;22(8):2669-76.

• Huiskens J, van Gulik TM, van Lienden KP, Engelbrecht MR, Meijer GA, van Grieken NC, Schriek J, Keijser A, Mol L, Molenaar IQ, Verhoef C, de Jong KP, Dejong KH, Kazemier G, Ruers TM, de Wilt JH, van Tinteren H, Punt CJ. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer. 2015 May 6;15(1):365.

• Husson O, Mols F, Ezendam NP, Schep G, van de Poll-Franse LV. Health-related quality of life is associated with physical activity levels among colorectal cancer survivors: a longitudinal, 3-year study of the PROFILES registry. J Cancer Surviv. 2015 Jan 9.

• Husson O, Mols F, van de Poll-Franse LV, Thong MS. The course of fatigue and its correlates in colorectal cancer survivors: a prospective cohort study of the PROFILES registry. Support Care Cancer. 2015 Nov;23(11):3361-71.

• Husson O, Vissers PA, Denollet J, Mols F. The role of personality in the course of health-related quality of life and disease-specific health status among colorectal cancer survivors: A prospective population-based study from the PROFILES registry.Acta Oncol. 2015 May;54(5):669-77.

• Koëter M, van Steenbergen LN, Lemmens VE, Rutten HJ, Roukema JA, Nieuwenhuijzen GA. Determinants in decision making for curative treatment and survival in patients with resectable oesophageal cancer in the Netherlands: a population-based study. Cancer Epidemiol. 2015 Dec;39(6):863-9.

• Lepage C, Capocaccia R, Hackl M, Lemmens V, Molina E, Pierannunzio D, Sant M, Trama A, Faivre J; EUROCARE-5 Working Grouph. Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999-2007: Results of EUROCARE-5. Eur J Cancer. 2015 Sep 5. pii: S0959-8049(15)00714-5.

• Mol L, Koopman M, Ottevanger PB, Punt CJ. Re: Generalizability of trial results to elderly medicare patients with advanced solid tumors. J Natl Cancer Inst. 2015 May 7;107(6):djv104.

• Mols F, Beijers AJ, Vreugdenhil G, Verhulst A, Schep G, Husson O. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv. 2015 Sep;9(3):512-22.

• Orsini RG, Verhoeven RH, Lemmens VE, van Steenbergen LN, de Hingh IH, Nieuwenhuijzen GA, Rutten HJ. Comparable survival for young rectal cancer patients, despite unfavourable morphology and more advanced-stage disease. Eur J Cancer. 2015 Sep;51(13):1675-82.

• Razenberg LG, van Gestel YR, Lemmens VE, de Hingh IH, Creemers GJ. Bevacizumab in Addition to Palliative Chemotherapy for Patients With Peritoneal Carcinomatosis of Colorectal Origin: A Nationwide Population-Based Study. Clin Colorectal Cancer. 2015 Dec 17. pii: S1533-0028(15)00157-7.

• Razenberg LG, van Gestel YR, Lemmens VE, de Wilt JH, Creemers GJ, de Hingh IH. The Prognostic Relevance of Histological Subtype in Patients With Peritoneal Metastases From Colorectal Cancer: A Nationwide Population-Based Study.Clin Colorectal Cancer. 2015 Dec;14(4):e13-9.

• Razenberg LG, van Gestel YR, Creemers GJ, Verwaal VJ, Lemmens VE, de Hingh IH. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands. Eur J Surg Oncol. 2015 Apr;41(4):466-71.

• Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015 May 9;385(9980):1843-52.

• Speelman AD, van Gestel YR, Rutten HJ, de Hingh IH, Lemmens VE. Changes in gastrointestinal cancer resection rates. Br J Surg. 2015 Aug;102(9):1114-22.

• Stegeman I, van Doorn SC, Mundt MW, Mallant-Hent RC, Bongers E, Elferink MA, Fockens P, Stroobants AK, Bossuyt PM, Dekker E. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening.Cancer Epidemiol. 2015 Jun;39(3):388-93.

• 't Lam-Boer J, Al Ali C, Verhoeven RH, Roumen RM, Lemmens VE, Rijken AM, De Wilt JH. Large variation in the utilization of liver resections in stage IV colorectal cancer patients with metastases confined to the liver. Eur J Surg Oncol. 2015 Sep;41(9):1217-25.

• Talsma AK, Damhuis RA, Steyerberg EW, Rosman C, van Lanschot JJ, Wijnhoven BP. Determinants of improved survival after oesophagectomy for cancer. Br J Surg. 2015 May;102(6):668-75.

• Trip AK, Stiekema J, Visser O, Dikken JL, Cats A, Boot H, van Sandick JW, Jansen EP, Verheij M. Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study.Acta Oncol. 2015 Nov;54(10):1754-62.

• van der Geest LG, Lam-Boer J, Koopman M, Verhoef C, Elferink MA, de Wilt JH. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015 Jun;32(5):457-65.

• van der Geest LG, van Meer S, Schrier JG, Ijzermans JN, Klümpen HJ, van Erpecum KJ, de Man RA. Survival in relation to hospital type after resection or sorafenib treatment for hepatocellular carcinoma in The Netherlands. Clin Res Hepatol Gastroenterol. 2015 Apr 3. pii: S2210-7401(15)00042-X.

• van Erning FN, Lemmens VE. Adequacy of lymph node yield and staging in rectal cancer should not be determined based on a minimum number of lymph nodes evaluated. Int J Colorectal Dis. 2016 Jan;31(1):149.

• van Erning FN, Janssen-Heijnen ML, Creemers GJ, Pruijt HF, Maas HA, Lemmens VE. Deciding on adjuvant chemotherapy for elderly stage III colon cancer patients: A qualitative insight into the perspectives of surgeons and medical oncologists. J Geriatr Oncol. 2015 May;6(3):219-24.

• van Erning FN, Rutten HJ, van den Berg HA, Lemmens VE, van Halteren HK. Effect of adjuvant chemotherapy on recurrence-free survival varies by neo-adjuvant treatment in patients with stage III rectal cancer. Eur J Surg Oncol. 2015 Dec;41(12):1630-5.

• van Erning FN, Elferink MA, Bos AC, Lemmens, VE. RE: Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer. J Natl Cancer Inst. 2015 Sep;107(9).

• van Hoeve JC, Elferink MA, Klaase JM, Kouwenhoven EA, Schiphorst PP, Siesling S. Long-term effects of a regional care pathway for patients with rectal cancer. Int J Colorectal Dis. 2015 Jun;30(6):787-95.

• van Oudheusden TR, Nienhuijs SW, Luyer MD, Nieuwenhuijzen GA, Lemmens VE, Rutten HJ, de Hingh IH. Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: A systematic review. Eur J Surg Oncol. 2015 Oct;41(10):1269-77. doi: 10.1016/j.ejso.2015.05.018. Epub 2015 Jul 3. Review.

• van Oudheusden TR, Lemmens VE, Braam HJ, van Ramshorst B, Meijerink J, Te Velde EA, Mehta AM, Verwaal VJ, de Hingh IH. Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands. Surgery. 2015 Jun;157(6):1023-7.

• van Oudheusden TR, Razenberg LG, van Gestel YR, Creemers GJ, Lemmens VE, de Hingh IH. Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin. Sci Rep. 2015 Dec 21;5:18632.

• van Putten M, Husson O, Mols F, Luyer MD, van de Poll-Franse LV, Ezendam NP. Correlates of physical activity among colorectal cancer survivors: results from the longitudinal population-based profiles registry. Support Care Cancer. 2016 Feb;24(2):573-83.

• van Putten M, Verhoeven RH, van Sandick JW, Plukker JT, Lemmens VE, Wijnhoven BP, Nieuwenhuijzen GA. Hospital of diagnosis and probability of having surgical treatment for resectable gastric cancer. Br J Surg. 2016 Feb;103(3):233-41.

• van Rijssen LB, van der Geest LG, Bollen TL, Bruno MJ, van der Gaast A, Veerbeek L, Ten Kate FJ, Busch OR. National compliance to an evidence-based multidisciplinary guideline on pancreatic and periampullary carcinoma. Pancreatology. 2015 Oct 26. pii: S1424-3903(15)00672-9.

• van Vulpen JK, Velthuis MJ, Steins Bisschop CN, Travier N, van den Buijs BJ, Backx FJ, Los M, Erdkamp FL, Bloemendal HJ, Koopman M, de Roos MA, Verhaar MJ, Ten Bokkel-Huinink D, van der Wall E, Peeters PH, May AM. Effects of an Exercise Program in Colon Cancer Patients Undergoing Chemotherapy. Med Sci Sports Exerc. 2015 Dec 21.

• Verhaar S, Vissers PA, Maas H, van de Poll-Franse LV, van Erning FN, Mols F. Treatment-related differences in health related quality of life and disease specific symptoms among colon cancer survivors: Results from the population-based PROFILES registry. Eur J Cancer. 2015 Jul;51(10):1263-73.

• Vissers PA, Thong MS, Pouwer F, Creemers GJ, Slooter GD, van de Poll-Franse LV. Prospectively measured lifestyle factors and BMI explain differences in health-related quality of life between colorectal cancer patients with and without comorbid diabetes. Support Care Cancer. 2015 Dec 30.

• Vissers PA, Mols F, Thong MS, Pouwer F, Vreugdenhil G, van de Poll-Franse LV. The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients: results from the PROFILES registry. J Cancer Surviv. 2015 Sep;9(3):523-31.

• Vogelaar FJ, Abegg R, van der Linden JC, Cornelisse HG, van Dorsten FR, Lemmens VE, Bosscha K. Epidural analgesia associated with better survival in colon cancer. Int J Colorectal Dis. 2015 Aug;30(8):1103-7.

• Vogelaar FJ, Lips DJ, van Dorsten FR, Lemmens VE, Bosscha K. Impact of anaesthetic technique on survival in colon cancer: a review of the literature. Gastroenterol Rep (Oxf). 2015 Feb 16. pii: gov001. Review.

• Vogelaar F, van Erning F, Reimers M, Van Der Linden J, Pruijt J, Van Den Brule A, Bosscha K. The prognostic value of Microsatellite Instability, KRAS, BRAF and PIK3CA mutations in stage II colon cancer patients. Mol Med. 2015 Dec 17:1-26.

• Weren RD, Venkatachalam R, Cazier JB, Farin HF, Kets CM, de Voer RM, Vreede L, Verwiel ET, van Asseldonk M, Kamping EJ, Kiemeney LA, Neveling K, Aben KK, Carvajal-Carmona L, Nagtegaal ID, Schackert HK, Clevers H, van de Wetering M, Tomlinson IP, Ligtenberg MJ, Hoogerbrugge N, Geurts van Kessel A, Kuiper RP. Germline deletions in the tumour suppressor gene FOCAD are associated with polyposis and colorectal cancer development. J Pathol. 2015 Jun;236(2):155-164.

• Zanders MM, van Herk-Sukel MP, Vissers PA, Herings RM, Haak HR, van de Poll-Franse LV. Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another? Br J Cancer. 2015 Jul 28;113(3):403-10.

• Zijlstra M, Bernards N, de Hingh IH, van de Wouw AJ, Goey SH, Jacobs EM, Lemmens VE, Creemers GJ. Does long-term survival exist in pancreatic adenocarcinoma? Acta Oncol. 2016 Mar;55(3):259-64.

Urinewegen

• Aben KK, van der Heijden AG, Kiemeney LA. Trends in incidentie, prognose en sterfte bij spierinvasief blaascarcinoom.Tijdschr Urol (2015) 5:184-192.

• Bruins HM, Aben KK, Arends TJ, van der Heijden AG, Witjes AJ. The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis. Urol Oncol. 2015 Dec 15. pii: S1078-1439(15)00558-X.

• Cremers RG, Galesloot TE, Aben KK, van Oort IM, Vasen HF, Vermeulen SH, Kiemeney LA. Known susceptibility SNPs for sporadic prostate cancer show a similar association with "hereditary" prostate cancer. Prostate. 2015 Apr 1;75(5):474-83.

• Cuypers M, Lamers RE, Kil PJ, van de Poll-Franse LV, de Vries M. Impact of a web-based treatment decision aid for early-stage prostate cancer on shared decision-making and health outcomes: study protocol for a randomized controlled trial. Trials. 2015 May 27;16(1):231.

• Derikx LA, Nissen LH, Drenth JP, van Herpen CM, Kievit W, Verhoeven RH, Mulders PF, Kaa CA, Boers-Sonderen MJ, van den Heuvel TR, Pierik M, Nagtegaal ID, Hoentjen F; Dutch Initiative on Crohn and Colitis (ICC); PALGA group; IBD/RCC group. Better survival of renal cell carcinoma in patients with inflammatory bowel disease. Oncotarget. 2015 Nov 10;6(35):38336-38347.

• Hermans TJ, Fransen van de Putte EE, Horenblas S, Lemmens V, Aben K, van der Heijden MS, Beerepoot LV, Verhoeven RH, van Rhijn BW. Perioperative treatment and radical cystectomy for bladder cancer - a population based trend analysis of 10,338 patients in the Netherlands. Eur J Cancer. 2016 Feb;54:18-26.

• Lamers RE, Cuypers M, Husson O, de Vries M, Kil PJ, Ruud Bosch JL, van de Poll-Franse LV. Patients are dissatisfied with information provision: perceived information provision and quality of life in prostate cancer patients. Psychooncology. 2015 Sep 25.

• Richters A, Derks J, Fossion LM, Kil PJ, Verhoeven RH, Aarts MJ. Presence and Number of Positive Surgical Margins after Radical Prostatectomy for Prostate Cancer: Effect on Oncological Outcome in a Population-Based Cohort. Urol Int. 2015 Nov 3.

• Valdagni R, Van Poppel H, Aitchison M, Albers P, Berthold D, Bossi A, Brausi M, Denis L, Drudge-Coates L, De Santis M, Feick G, Harrison C, Haustermans K, Hollywood D, Hoyer M, Hummel H, Mason M, Mirone V, Müller SC, Parker C, Saghatchian M, Sternberg CN, Tombal B, van Muilekom E, Watson M, Wesselmann S, Wiegel T, Magnani T, Costa A. Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. Crit Rev Oncol Hematol. 2015 Aug;95(2):133-43. Review.

• Voogd AC, Verhoeven RH. Treatment of the Primary Tumour in the Presence of Metastases: Lessons from Breast Cancer. Eur Urol. 2015 Jun 29. pii: S0302-2838(15)00527-8.

Vrouwelijke geslachtsorganen

• Amankwah EK, Aben KK, Phelan CM et al. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genet Epidemiol. 2015 Sep 24.

• Becker JH, Ezendam NP, Boll D, van der Aa M, Pijnenborg JM. Effects of surgical volumes on the survival of endometrial carcinoma. Gynecol Oncol. 2015 Sep 5. pii: S0090-8258(15)30118-9.

• Bolton KL, Aben KK, Gayther SA et al. Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2015 Dec 29;48(1):101.

• Chornokur G, Aben KK, Phelan CM et al. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS One 2015 Jun 19;10(6):e0128106.

• de Boer SM, Nout RA, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, Oerlemans S, Putter H, Verhoeven-Adema KW, Nijman HW, Creutzberg CL. Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial. Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):797-809.

• Jim HS, Aben KK, Phelan CM et al. Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). J Genet Genome Res. 2015;2(2). pii: 017.

• Kar SP, Aben KK, Pharoah PD et al. Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1574-84.

• Kelemen LE, Lawrenson K, Tyrer J, Li Q, Lee JM, Seo JH, Phelan CM, Beesley J, Chen X, Spindler TJ, Aben KK, Anton-Culver H, Antonenkova N; Australian Cancer Study; Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium. Genome-wide significant risk associations for mucinous ovarian carcinoma. Nat Genet. 2015 Aug;47(8):888-97.

• Kuchenbaecker KB, Aben KK, Chenevix-Trench G et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015 Feb;47(2):164-71.

• Lawrenson K, Aben KK, Freedman ML et al. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nat Commun. 2015 Sep 22;6:8234.

• Lawrenson K, Aben KK, Schildkraut JM et al. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer.Carcinogenesis. 2015 Nov;36(11):1341-53.

• Lee AW, Templeman C, Stram DA, Beesley J, Tyrer J, Berchuck A, Pharoah PP, Chenevix-Trench G, Pearce CL; Ovarian Cancer Association Consortium (Aben KK). Evidence of a genetic link between endometriosis and ovarian cancer. Fertil Steril. 2016 Jan;105(1):35-43.e10.

• Lu Y, Aben KK, Macgregor S et al. Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Hum Mol Genet. 2015 Jul 30. pii: ddv306.

• Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, Aben KK, Goode EL et al. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Gynecol Oncol. 2015 May 2. pii: S0090-8258(15)00863-X. Review.

• Reynaers EA, Ezendam NP, Pijnenborg JM. Comparable outcome between endometrioid and non-endometrioid tumors in patients with early-stage high-grade endometrial cancer. J Surg Oncol. 2015 May;111(6):790-4.

• Sant M, Chirlaque Lopez MD, Agresti R, Sánchez Pérez MJ, Holleczek B, Bielska-Lasota M, Dimitrova N, Innos K, Katalinic A, Langseth H, Larrañaga N, Rossi S, Siesling S, Minicozzi P; EUROCARE-5 Working Group. Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EUROCARE-5 study. Eur J Cancer. 2015 Sep 6. pii: S0959-8049(15)00702-9.

• van der Putten LJ, Geels YP, Ezendam NP, van der Putten HW, Snijders MP, van de Poll-Franse LV, Pijnenborg JM. Lymphovascular space invasion and the treatment of stage I endometrioid endometrial cancer. Int J Gynecol Cancer. 2015 Jan;25(1):75-80.

• van Kruchten M, van der Marel P, de Munck L, Hollema H, Arts H, Timmer-Bosscha H, de Vries E, Hospers G, Reyners A. Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecol Oncol. 2015 Sep;138(3):634-9.

• Visser NC, Bulten J, van der Wurff AA, Boss EA, Bronkhorst CM, Feijen HW, Haartsen JE, van Herk HA, de Kievit IM, Klinkhamer PJ, Pijlman BM, Snijders MP, Vandenput I, Vos MC, de Wit PE, van de Poll-Franse LV, Massuger LF, Pijnenborg JM. PIpelle Prospective ENDOmetrial carcinoma (PIPENDO) study, pre-operative recognition of high risk endometrial carcinoma: a multicentre prospective cohort study. BMC Cancer. 2015 Jun 30;15:487.